Tesla
TSLA
Broadcom
AVGO
Netflix
NFLX
Advanced Micro Devices
AMD
Alphabet-C
GOOG
US Stock MarketDetailed Quotes
CATX Perspective Therapeutics
- 2.3600
- -0.0900-3.67%
Close Mar 19 16:00 ET
- 2.3900
- +0.0300+1.27%
Post 20:01 ET
159.51MMarket Cap-1.58P/E (TTM)
2.4703High2.3600Low675.83KVolume2.4500Open2.4500Pre Close1.62MTurnover1.41%Turnover RatioLossP/E (Static)67.59MShares19.050052wk High0.49P/B113.51MFloat Cap2.320052wk Low--Dividend TTM48.10MShs Float85.0000Historical High--Div YieldTTM4.50%Amplitude0.0300Historical Low2.3900Avg Price1Lot Size
Perspective Therapeutics News
Perspective Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Perspective Therapeutics Analyst Ratings
LifeSci Capital Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $21
Promising Developments and Strategic Trial Design Justify Buy Rating for Perspective Therapeutics
H.C. Wainwright Initiates Perspective Therapeutics(CATX.US) With Buy Rating, Announces Target Price $10
RBC Capital Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $16
Analysts Offer Insights on Healthcare Companies: Zai Lab (ZLAB), Perspective Therapeutics (CATX) and Edesa Biotech (EDSA)
Brookline Capital Initiates Perspective Therapeutics(CATX.US) With Buy Rating, Announces Target Price $11
Brookline Initiates Perspective Therapeutics at Buy With $11 Price Target
Perspective Therapeutics Analyst Ratings
Scotiabank Initiates Coverage On Perspective Therapeutics With Sector Outperform Rating, Announces Price Target of $15
LifeSci Capital Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $21
Promising Outlook for Perspective Therapeutics: Buy Rating Backed by Positive Trial Data and Market Positioning
Oppenheimer Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $16
Truist Financial Maintains Perspective Therapeutics(CATX.US) With Buy Rating
BofA Securities Maintains Perspective Therapeutics(CATX.US) With Hold Rating, Maintains Target Price $6
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX), Axsome Therapeutics (AXSM) and HCA Healthcare (HCA)
JonesTrading Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $21
BofA Securities Maintains Perspective Therapeutics(CATX.US) With Hold Rating, Maintains Target Price $6
RBC Capital Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $16
Trending Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.